Search the Newsreel

Syndax Pharmaceuticals, Inc. Podcast | SNDX Podcasts & Related Content

This article provides an overview of Syndax Pharmaceuticals, Inc. (SNDX), including its current stock price, market data, and related content categories such as news, earnings calls, financial information, and podcasts. It highlights the company's stock performance for the day and key financial metrics, while …

Syndax Pharmaceuticals Inc (SNDX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Syndax Pharmaceuticals Inc (SNDX), noting its current valuation score of 7.45 within the Biotechnology & Medical Research industry. It details the company's P/E ratio, which is -7.45, and mentions that P/B, P/S, and P/CF data have not …

Orbimed Advisors LLC Invests $22.48 Million in Syndax Pharmaceuticals, Inc. $SNDX

Orbimed Advisors LLC has made a new investment of $22.48 million in Syndax Pharmaceuticals, acquiring 962,300 shares, representing 1.09% of the company. Despite insider selling, analysts maintain a "Moderate Buy" rating with a positive price target. Syndax Pharmaceuticals reported a smaller-than-expected quarterly loss and …

Syndax Pharmaceuticals (SNDX) Projected to Announce Quarterly Earnings on Monday

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages

Syndax Pharmaceuticals (NASDAQ:SNDX) has received an average rating of "Moderate Buy" from thirteen brokerages, with an average 1-year price target of $42.55. Despite recent analyst upgrades and reaffirmed ratings, the stock was down 1.9% at $20.81, and quarterly revenue missed expectations, although EPS beat …

Granahan Investment Management LLC Cuts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX

Granahan Investment Management LLC reduced its stake in Syndax Pharmaceuticals (NASDAQ:SNDX) by 16.5% during the first quarter, selling 60,472 shares and retaining 306,321 shares valued at $7.16 million. This reduction comes amid other institutional investors making varied changes to their positions and recent insider …

Syndax Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SNDX

This article provides a revenue breakdown for Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX). The company generated $172.35 million USD last year, primarily from its Pharmaceuticals segment and the United States market. This marks a significant increase from the previous year's revenue of $23.68 million USD.

Price to sales forward of Syndax Pharmaceuticals Inc – SWB:1T3

This article provides a brief financial update on Syndax Pharmaceuticals Inc (SWB:1T3) from the Stuttgart Stock Exchange, specifically focusing on its "Price to sales forward" metric. The content indicates that the market is closed, with no trades, and offers a link to view the …

SNDX|Syndax Pharmaceuticals Inc|Price:20.830|Chg%:+0.020

TradingKey provides a comprehensive stock analysis of Syndax Pharmaceuticals Inc (SNDX), highlighting its strong fundamentals, high growth potential, and "Buy" rating from multiple analysts with a target price of $40.55. The company's valuation is considered fair within the Biotechnology & Medical Research industry, despite …

Is Syndax (SNDX) Quietly Redefining Its R&D Focus With New Menin and EGFR Programs?

Syndax Pharmaceuticals (SNDX) recently held an R&D event, unveiling two new drug candidates: SNDX-4321 for EGFR-mutant NSCLC and SNDX-62122 for myelofibrosis, alongside updates on its late-stage programs. These additions aim to diversify its pipeline beyond existing commercial assets, targeting difficult-to-treat cancers with high unmet …

Technical Reactions to SNDX Trends in Macro Strategies

This article provides a technical analysis of Syndax Pharmaceuticals Inc. (NASDAQ: SNDX), highlighting a weak near-term sentiment that could precede shifts in mid and long-term outlook. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The …

Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary

Syndax Pharmaceuticals presented at the TD Cowen 46th Annual Health Care Conference, highlighting the successful launches of their two commercial products, Revuforj and Niktimvo, which generated $125 million and $152 million respectively in their first year/11 months. The company is well-capitalized with $400 million …

Syndax Pharmaceuticals Inc. (SNDX) Q3 2024 Earnings Report - Results, Call & Slides

Syndax Pharmaceuticals (SNDX) reported its Q3 2024 earnings, beating analyst expectations with an actual EPS of -$0.98 against a consensus of -$1.07, and revenue of $12.50M compared to an expected $9.32M. The company's next earnings date is estimated for August 10, 2026. The report …

Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know

Syndax Pharmaceuticals (SNDX) has seen an 8.20% increase in stock price over the past week, outperforming its industry and the S&P 500. With a Zacks Momentum Style Score of B and a Zacks Rank of #2 (Buy), the company shows strong short-term price activity …

Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story

Syndax Pharmaceuticals (SNDX) recently held an R&D event highlighting new oncology and fibrosis projects, drawing attention to its stock. Despite recent short-term dips, the company has seen significant long-term growth with a 1-year total shareholder return of over 150%. A current analysis suggests the …

Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34

Goldman Sachs has reaffirmed its Buy rating for Syndax Pharmaceuticals (SNDX.US) and maintained its price target of $34. This indicates continued analyst confidence in the company's stock performance.

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Syndax Pharmaceuticals will showcase its late-stage programs and introduce new pipeline assets, SNDX-4321 and SNDX-62122, at its upcoming R&D Event. The company is expanding its portfolio in oncology and fibrotic diseases by leveraging both external innovation and internally developed next-generation menin inhibitors. Key opinion …

Syndax Pharmaceuticals (SNDX) R&D Day 2026 Summary

Syndax Pharmaceuticals (SNDX) held its R&D Day 2026, highlighting a deep and expanding pipeline including Revuforj, Niktimvo, SNDX-4321, and SNDX-62122, targeting various cancers and fibrotic diseases. The company expects four innovative assets in the clinic by 2027, with multiple near-term catalysts and blockbuster potential. …

H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy

H.C. Wainwright reiterated a Buy rating and a $40.00 price target for Syndax Pharmaceuticals (NASDAQ:SNDX) after the company's research and development day. The analyst firm highlighted two new assets, SNDX-62122 and SNDX-4321, with SNDX-62122 showing promise as a next-generation menin inhibitor for myelofibrosis. Syndax …

SNDX6417984 Bond Coupon Profile — Rate & Payments

This article provides a bond coupon profile for Syndax Pharmaceuticals, Inc. (SNDX6417984). It indicates a current coupon rate of 2.25% with the next interest payment scheduled for December 15, 2026. The profile offers an overview of the bond's interest payments and redemption details.